A young woman treated for suspected methaemoglobinaemia instead experiences worsening haemolysis that reveals a previously ...
6-month commercial pilot demonstrated increasing demand among prescribers Expansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaign ...
Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA) ...
Warnings and Precautions Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA ® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis. G6PD ...
New Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progress Total addressable market (TAM) for ARAKODA for Human Babesiosis is ...
New 8-count bottles now available through major retail pharmacies ARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June ...
To test tubes, 16 by 100 mm., are added 10 mg. of sodium ascorbate § and 5 mg. of glucose. These tubes are stoppered and may be stored indefinitely at -20°C. A 2.0-ml. aliquot of whole blood ...
WASHINGTON, D.C., April 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback